Abstract
Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P
| Original language | English |
|---|---|
| Article number | e512 |
| Journal | Translational Psychiatry |
| Volume | 5 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jan 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry
- Cellular and Molecular Neuroscience
Cite this
A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. / Errico, F.; D'Argenio, V.; Sforazzini, F.; Iasevoli, F.; Squillace, M.; Guerri, G.; Napolitano, F.; Angrisano, T.; Di Maio, A.; Keller, S.; Vitucci, D.; Galbusera, A.; Chiariotti, L.; Bertolino, A.; De Bartolomeis, A.; Salvatore, F.; Gozzi, A.; Usiello, A.
In: Translational Psychiatry, Vol. 5, No. 2, e512, 01.01.2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice
AU - Errico, F.
AU - D'Argenio, V.
AU - Sforazzini, F.
AU - Iasevoli, F.
AU - Squillace, M.
AU - Guerri, G.
AU - Napolitano, F.
AU - Angrisano, T.
AU - Di Maio, A.
AU - Keller, S.
AU - Vitucci, D.
AU - Galbusera, A.
AU - Chiariotti, L.
AU - Bertolino, A.
AU - De Bartolomeis, A.
AU - Salvatore, F.
AU - Gozzi, A.
AU - Usiello, A.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P
AB - Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P
UR - http://www.scopus.com/inward/record.url?scp=84927722951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927722951&partnerID=8YFLogxK
U2 - 10.1038/tp.2015.2
DO - 10.1038/tp.2015.2
M3 - Article
VL - 5
JO - Translational Psychiatry
JF - Translational Psychiatry
SN - 2158-3188
IS - 2
M1 - e512
ER -